MHRA-101704-PIP01-24

Key Facts

Active Substance
Active Substance:
  • Nucresiran sodium
Invented Name
Not yet available
PIP Number MHRA-101704-PIP01-24
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
  • Neurology
  • Cardiovascular Diseases
Conditions / Indications
Conditions / Indications:
  • Treatment of transthyretin amyloidosis
Route(s) of administration
Route(s) of administration:
  • Subcutaneous use
PIP applicant
  • Alnylam Netherlands B.V
  • Country Netherlands
  • Tel 0031203697868
  • Email infor@alnylam.com
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Nucresiran sodium.pdf
Published Date 23/06/2025